Azoy Alexander 4
4 · Arcus Biosciences, Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Arcus (RCUS) Chief Accounting Officer Azoy Alexander Sells 2,562 Shares
What Happened
- Azoy Alexander, Chief Accounting Officer of Arcus Biosciences (RCUS), sold 2,562 shares on 2026-06-01 in open-market transactions. The weighted-average sale price was $25.77 per share, for total proceeds of approximately $66,024. The sales were reported on a Form 4 filed the same day.
Key Details
- Transaction date: 2026-06-01 (reported timely).
- Action: Sale (code S) — 2,562 shares sold; weighted average price $25.77; total ~$66,024.
- Price range: Shares were sold in multiple trades at prices between $25.67 and $25.90 (per filing).
- Prior purchase: Footnote indicates these 2,562 shares were purchased on 2026-05-29 through the company’s Employee Stock Purchase Plan (ESPP).
- Trading plan: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- Ownership after sale: The filing notes owned shares include unvested RSUs, but the exact post-sale total is not specified in the provided summary (footnote references unvested RSU inclusion).
Context
- This was a sale executed under a pre-established 10b5-1 plan and involved recently acquired ESPP shares. Such automated plan sales and ESPP sell-offs are commonly routine and do not by themselves indicate insider sentiment about the company’s prospects.
Insider Transaction Report
Form 4
Azoy Alexander
Chief Accounting Officer
Transactions
- Sale
Common Stock
[F1][F2][F3][F4]2026-06-01$25.77/sh−2,562$66,024→ 39,581 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]Includes the unvested portion of the Reporting Person's RSU grants.
Signature
/s/ Carolyn Tang, Attorney-in-Fact|2026-06-01